YEYihsien Enatsu

Yihsien Enatsu

*This is an algorithmically generated author record based on publicly available information.

Yihsien Enatsu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Differences in clinical outcomes between men with mosaic Klinefelter syndrome and those with non‐mosaic Klinefelter syndrome

    by Juri Tsukamoto, Noritoshi Enatsu, Eri Nakahara, Kohyu Furuhashi, Koji Chiba, Yihsien Enatsu, Yuri Mizusawa, Eri Okamoto, Shoji Kokeguchi, Masahide Shiotani

    Purpose: This study compared the clinical outcomes of men with Klinfelter syndrome based on karyotype.Methods: The authors analyzed the outcomes of microdissection testicular sperm extraction (micro‐TESE) performed on 57 patients with Klinfelter syndrome (KS) at our clinic.Results: The average ages of the non‐mosaic and mosaic KS groups were 32.2 ± 4.8 and 45.9 ± 13.1 years, respectively. The sperm retrieval rates of the non‐mosaic and mosaic KS groups were 46.5% (20/43) and 50.0% (7/14), respectively. The fertilization rates after intracytoplasmic sperm injection did not significantly differ between the non‐mosaic and mosaic KS groups. The mosaic KS group had higher cleavage and blastocyst development rates than the non‐mosaic KS group (72.2% vs. 96.2% and 30.5% vs. 44.7%, respectively). The group using motile sperm had better outcomes than the group using immotile sperm. The embryo transfer outcomes of the non‐mosaic and mosaic KS groups did not significantly differ (clinical pregnancy rate: 28.0% vs. 20.7%, miscarriage rate: 14.3% vs. 33.3%, production rate per transfer: 22.0% vs. 13.8%, and production rate per case: 58.8% vs. 57.1%).Conclusions: Compared with the non‐mosaic KS group, the mosaic KS group had significantly better intracytoplasmic sperm injection outcomes because of the higher utilization rate of motile sperm.


  • Open Access

    Clinical outcome of intrauterine infusion of platelet‐rich plasma in patients with recurrent implantation failure

    by Yihsien Enatsu, Noritoshi Enatsu, Kanako Kishi, Junko Otsuki, Toshiroh Iwasaki, Eri Okamoto, Shoji Kokeguchi, Masahide Shiotani

    Purpose: This study aimed to evaluate the effectiveness of intrauterine infusion of platelet‐rich plasma (PRP) before embryo transfer (ET) in recurrent implantation failure (RIF) cases.Methods: The authors retrospectively analyzed 54 ET cycles involving frozen and thawed high‐quality blastocysts after intrauterine PRP infusion between September 2019 and November 2020. All patients had a history of at least two times of implantation failure on ET. A total of 54 patients were categorized into two groups: thin endometrium (39 patients) and unexplained implantation failure (15 patients). In the thin‐endometrium group, the endometrial thickness (EMT) was <8.0 mm at cycle days 12–14 in the prior ET cycle.Results: Among the 54 ET cycles after PRP infusion, 31 (57.4%) were positive for human chorionic gonadotropin (hCG) and 27 (50%) achieved clinical pregnancy, which was significantly better than that in prior ET cycles without PRP infusion (27.2% and 9.6%, respectively). The EMT was not increased at ET date on the PRP cycle compared with that in the prior ET cycle in both patient groups. Moreover, EMT was not different between the hCG‐positive and hCG‐negative groups.Conclusion: Although intrauterine PRP infusion had no superior effect on increasing the EMT than conventional therapeutic agents, it resulted in high pregnancy rates in patients experiencing RIF with or without thin endometrium.


  • Open Access

    Effectiveness of high‐dose transvaginal progesterone supplementation for women who are undergoing a frozen‐thawed embryo transfer

    by Yihsien Enatsu, Noritoshi Enatsu, Kanako Kishi, Toshiro Iwasaki, Yukiko Matsumoto, Shoji Kokeguchi, Masahide Shiotani

    Purpose: To evaluate the effectiveness of high‐dose progesterone supplementation for women who are undergoing a frozen‐thawed embryo transfer (FET).Methods: Among the 2010 FET cycles that were included in the present study, 1188 were 1200 mg/d of vaginal progesterone, while 822 were 900 mg/d. The dose of progesterone that was used was decided by the treatment period and additional progesterone supplementation was used when the serum progesterone levels were <9 ng/mL on luteal day 5.Results: The clinical pregnancy rate was higher in the 1200 mg group than in the 900 mg group. The mean serum progesterone level on luteal day 5 in the 1200 mg and 900 mg groups was 12.6 ng/mL and 13.4 ng/mL, respectively. The rate of additional progesterone supplementation was higher in the 1200 mg group. A logistic regression analysis identified a younger age (≤37 years) and the use of 1200 mg progesterone as independent predictive factors for the clinical pregnancy outcome. The analysis of the infant outcomes revealed no significant difference in the distribution of birth ages and weights.Conclusion: High‐dose transvaginal progesterone of 1200 mg/d as luteal support contributed to good pregnancy outcomes.